Diagnostics News and Research

RSS

Neogen's new Soleris test detects yeast and mold in 48 hours

Neogen Corporation has developed an even quicker method to rapidly and accurately detect yeast and mold in food products. Neogen's new Soleris® test detects yeast and mold in 48 hours or less — conventional methods take up to 5 days.

7 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Abbott today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively.

7 Nov 2011

Abbott wins 2011 Scrip Award for Corporate Social Responsibility

Scrip, a leading global pharmaceutical and biotech news organisation, honored Abbott and its philanthropic foundation, the Abbott Fund, with a 2011 Scrip Award for Corporate Social Responsibility (CSR) at Scrip's seventh annual awards ceremony in London on Thursday evening.

5 Nov 2011

Princeton University's bone marrow research to prevent breast cancer metastasis

Two teams of Princeton University researchers will study bone marrow to help explain and potentially prevent breast cancer from spreading, with national research funding announced today by Susan G. Komen for the Cure.

5 Nov 2011

Siemens Healthcare to acquire MobileMD

Today, Siemens Healthcare announced that the company has entered into a definitive agreement to acquire all issued and outstanding equity of MobileMD, Inc., of Yardley, Pa., a provider of health information exchange (HIE) solutions.

From Siemens Healthineers 5 Nov 2011

Pall launches new Acrodisc MS syringe filter

Pall Corporation, today introduced the Pall Acrodisc MS Syringe Filter the first syringe filter certified for low extractables in high performance liquid chromatography/mass spectrometry (LCMS) applications.

From Pall Corporation 5 Nov 2011

MicroRNAs may predict risk of recurrence in post-resection gastric cancer patients

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results from a joint study by researchers at the Institutes of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Golda-Hasharon Hospital in Petach-Tikva, Israel show that in post-resection gastric cancer patients microRNAs may serve to predict the risk of recurrence.

4 Nov 2011

Experts look to India to develop accurate, affordable TB diagnostics

SciDev.Net examines tuberculosis (TB) in India, which has the world's highest TB burden, and some experts' hopes that researchers in the country can develop accurate and affordable diagnostic test kits.

4 Nov 2011

Using sub-nanometre cages to identify molecules

Reliable and accurate single-molecule medical diagnosis is a step closer to reality with the development a new technique by Cambridge University researchers which uses sub-nanometre “cages” to capture and identify molecules.

3 Nov 2011

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott scientists and independent researchers will highlight the latest research findings on HUMIRA (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.

3 Nov 2011

Allergy shots are cost-effective and deliver relief in weeks

Allergy shots, an age-old treatment for allergy sufferers, are getting a shot in the arm from new research. This proven therapy saves money; accelerated schedules deliver relief in weeks, rather than months; and alternative methods are on the horizon, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology in Boston, Nov 3-8.

3 Nov 2011

Biomoda submits new U.S. Patent application for CyPath lung cancer assay

Cancer diagnostics company Biomoda, Inc. filed an application for a new U.S. Patent that refines the use of fluorescent microscopy to increase the accuracy, sensitivity and specificity of the CyPath diagnostic assay for lung cancer.

3 Nov 2011

DexCom signs research and development agreement with Roche

Roche Diagnostics U.S., with its business unit Roche Diabetes Care, a leader in blood glucose monitoring and insulin delivery systems, and DexCom, Inc., a leader in continuous glucose monitoring systems, announced today that they have signed a research and development agreement.

From Roche Sequencing and Life Science 3 Nov 2011

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

2 Nov 2011

FDA grants Premarket Approval for Roche's IgM antibody to hepatitis B core antigen assay

Roche announced today that the U.S. Food and Drug Administration granted Premarket Approval for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the cobas e 601 analyzer, the immunoassay module of the cobas 6000 analyzer series for mid-volume laboratories.

From Roche Sequencing and Life Science 31 Oct 2011

Haemonetics second quarter net revenues increase 8% to $179.4 million

Haemonetics Corporation today reported second quarter 2012 GAAP net revenues of $179.4 million, up 8%, net income of $13.9 million, down 35%, and earnings per share of $0.54, down 36%. Excluding transformation costs and contingent consideration income, adjusted second quarter net income was $18.7 million, down 7%, and adjusted earnings per share was $0.72, down 9%. Excluding currency impacts, net revenue was up 6% in the quarter.

31 Oct 2011